# Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis

> **NCT02280616** · PHASE2 · COMPLETED · sponsor: **Dr. Falk Pharma GmbH** · enrollment: 76 (actual)

## Conditions studied

- Eosinophilic Esophagitis

## Interventions

- **DRUG:** low dose budesonide tablet
- **DRUG:** high dose budesonide tablet
- **DRUG:** high dose budesonide suspension
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02280616
- **Lead sponsor:** Dr. Falk Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2013-04
- **Final completion:** 2014-05
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2016-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02280616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02280616, "Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02280616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*